FDA Approves Tazarotene Lotion, 0.045%, for Acne Vulgaris
Tazarotene is the first acne treatment to be available in a lotion form, showing strong efficacy with favorable tolerability.
Related Articles
Declines in Pediatric Pneumococcal Complicated Pneumonia Evident Following Introduction of Higher Valent Vaccines
A systematic review reveals declining pediatric pneumococcal complicated pneumonia rates following the introduction of pneumococcal conjugate vaccine 13.
Zanidatamab Plus Chemotherapy Shows Promising Anti-Tumor Activity in Treatment of HER2-Mutated Breast Cancer
The data were presented at the ESMO Breast Cancer 2025 Annual Meeting.
FDA to Restrict Future COVID-19 Vaccine Recommendations to Older Adults, High-Risk Groups
In a major policy shift, officials from the FDA announced a new regulatory framework for COVID-19 vaccinations, prioritizing adults aged 65 and older and individuals…
Carefully Consider Optimal Timing of RSV Vaccination in Older Adults
Administration during peak vaccine effectiveness provides maximal protective benefit
Neoadjuvant Trastuzumab Deruxtecan Improves Pathologic Complete Response in Patients With HER2+ Early Breast Cancer
Trastuzumab deruxtecan was safe and efficacious prior to treatment with paclitaxel, trastuzumab, and pertuzumab.
RSV and Aging: Understanding Increased Vulnerability
New research reveals how aging weakens immune responses to RSV in older adults, increasing severity and hospitalization risks.
Launch of Generic Eltrombopag Expands Access for Patients With Thrombocytopenia, Aplastic Anemia
This new generic will impact both oncology and community pharmacists.
Several Comorbidities Found to Reduce Likelihood of Pneumococcal Vaccination, While Use of Implantable Devices Heightens Odds
A new study reveals that heart failure patients with implantable devices are more likely to receive the pneumococcal conjugate vaccine 13, impacting vaccination rates and…
Adding Pertuzumab to Trastuzumab and Chemotherapy Reduced Risk of Death by 17% in HER2+ Breast Cancer
New data reveals that combining pertuzumab with trastuzumab significantly improves survival rates in HER2+ breast cancer patients, reducing death risk by 17%.
High LDL Cholesterol Associated With Earlier Progression in Synchronous Metastatic Colorectal Cancer
In patients with synchronous metastatic colorectal cancer treated without curative intent, high low-density lipoprotein (LDL) cholesterol was associated with poor survival.